

Supplemental online content for:

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Angel Qin, MD; Songzhu Zhao, MSc; Abdul Miah, MD; Lai Wei, PhD; Sandipkumar Patel, MBBS; Andrew Johns, MD; Madison Grogan, BA; Erin M. Bertino, MD; Kai He, MD, PhD; Peter G. Shields, MD; Gregory P. Kalemkerian, MD; Shirish M. Gadgeel, MBBS; Nithya Ramnath, MBBS; Bryan J. Schneider, MD; Khaled A. Hassan, MD, MS; Nicholas Szerlip, MD; Zoey Chopra, BA; Sara Journey, BS; Jessica Waninger, BA, BS; Daniel Spakowicz, PhD; David P. Carbone, MD, PhD; Carolyn J. Presley, MD, MHS; Gregory A. Otterson, MD; Michael D. Green, MD, PhD; and Dwight H. Owen, MD, MSc

J Natl Compr Canc Netw 2021;19(8):915–921

eTable 1: Characteristics of Patients With mNSCLC Treated Using ICIs

eTable 2: Characteristics of Patients With mNSCLC Treated Using Chemotherapy Only

eTable 1. Characteristics of Patients With mNSCLC Treated Using ICIs

	BM Absent n (%)	BM Present n (%)	Total n (%)	P Value
Total, n	206	124	330	
Median age at ICI (IQR), y	63.4 (57.6–72.7)	63.5 (56.8–71.2)	63.4 (57.3–71.7)	.646
Sex				.753
Male	96 (46.6)	60 (48.4)	156 (47.3)	
Female	110 (53.4)	64 (51.6)	174 (52.7)	
Histology				.490
Adenocarcinoma	137 (66.5)	82 (66.1)	219 (66.4)	
Squamous	56 (27.2)	30 (24.2)	86 (26.1)	
Other	13 (6.3)	12 (9.7)	25 (7.6)	
KRAS mutation				.736
0	153 (74.3)	90 (72.6)	243 (73.6)	
1	53 (25.7)	34 (27.4)	87 (26.4)	
EGFR mutation				.790
0	200 (97.1)	121 (97.6)	321 (97.3)	
1	6 (2.9)	3 (2.4)	9 (2.7)	
TP53 mutation				.715
0	163 (79.1)	96 (77.4)	259 (78.5)	
1	43 (20.9)	28 (22.6)	71 (21.5)	
ECOG PS				.519
Missing	2	2	4	
0	39 (18.9)	18 (14.5)	57 (17.3)	
1	117 (56.8)	67 (54.0)	184 (55.8)	
2	44 (21.4)	34 (27.4)	78 (23.6)	
≥3	4 (1.9)	3 (2.4)	7 (2.1)	
Smoking status				.838
Never	25 (12.1)	16 (12.9)	41 (12.4)	
Current/Former	181 (87.9)	108 (87.1)	289 (87.6)	
Metastatic burden				<.001
Missing	0	1	1 (0.3)	
1	90 (43.7)	19 (15.5)	109 (33.1)	
2	76 (36.9)	47 (38.2)	123 (37.4)	
≥3	40 (19.4)	57 (46.3)	97 (29.5)	
PD-L1				.262
Missing	143 (69.4)	91 (73.3)	234 (70.9)	
Negative	16 (7.8)	12 (9.7)	28 (8.5)	
Positive	47 (22.8)	21 (17.0)	68 (20.6)	
Line of therapy				.567
1	57 (27.7)	34 (27.4)	91 (27.6)	
2	96 (46.6)	64 (51.6)	160 (48.5)	
3	53 (25.7)	26 (21.0)	79 (23.9)	

Abbreviations: BM, bone metastases; ICI, immune checkpoint inhibitor; IQR, interquartile ratio; mNSCLC, metastatic non-small cell lung cancer; PS, performance status.

eTable 2. Characteristics of Patients With mNSCLC Treated Using Chemotherapy Only

Characteristic	n (%)
Total, N	166
Age at therapy, y	66
Sex	
Male	90 (54.2)
Female	76 (45.8)
Smoking status	
Never	25 (15.1)
Current/Former	141 (84.9)
Histology	
Adenocarcinoma	131 (78.9)
Squamous	22 (13.3)
Other	13 (7.8)
Stage at therapy	
IV	166 (100.0)
Therapy	
Carboplatin/Pemetrexed	49 (29.5)
Gemcitabine	27 (16.3)
Carboplatin/Paclitaxel	13 (7.8)
Pemetrexed	15 (9.0)
EGFR inhibitors	15 (9.0)
Other	47 (28.3)

Abbreviation: mNSCLC, metastatic non–small cell lung cancer.